For Immediate Release
Chicago, IL –December 12, 2019 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Novartis (NVS - Free Report) , AbbVie (ABBV - Free Report) , Sanofi (SNY - Free Report) , Pioneer Natural Resources (PXD - Free Report) and Aqua America .
Here are highlights from Wednesday’s Analyst Blog:
Top Research Reports for Novartis, AbbVie and Sanofi
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Novartis, AbbVie and Sanofi. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today’s research reports here >>>
Novartis’s shares have outperformed the Zacks Large-Cap Pharmaceuticals industry year to date (8.2% vs. 8.1%). The Zacks analyst believes that Novartis’ performance in the year so far has been stellar on key drugs like Cosentyx and Entresto, its contribution from Zolgensma, and the Xiidra acquisition.
The impending acquisition of The Medicines Company should broaden its portfolio. New launches like Piqray and Beovu should further propel performance in the upcoming quarters. A strong uptake is expected particularly from Beovu as it is the first FDA-approved anti-VEGF to offer greater fluid resolution compared to Eylea.
However, price erosion in the United States has adversely impacted the generic business. Recently, Novartis has restructured its business and spun off the eye-care unit, Alcon, to become a core drug-focused company. However, pipeline setbacks and generic competition for key drugs are concerns
(You can read the full research report on Novartis here >>>)
Shares of AbbVie have gained 22.2% in the past three months against the Zacks Large-Cap Pharmaceuticals industry’s rise of 9.3%. The Zacks analyst believes that AbbVie’s Humira is performing well driven by strong demand trends amid new competition.
Imbruvica has multibillion-dollar potential. AbbVie has been successful in expanding approvals for its cancer drugs, Imbruvica and Venclexta. It also has an impressive late-stage pipeline. It gained approvals for two new drugs with significant potential, Skyrizi (risankizumab) and Rinvoq this year. Both are off to a strong start.
The acquisition of Allergan, if successful, should diversify AbbVie’s revenue base and accelerate its non-Humira business. Sales erosion due to direct biosimilar competition to Humira in international markets is a big headwind. Also, the decline in HCV sales is a concern.
(You can read the full research report on AbbVie here >>>)
Sanofi's shares have gained 11.2% over the past six months against the Zacks Large Cap Pharmaceuticals industry's rise of 5%. The Zacks analyst believes that Sanofi’s focus on streamlining operations and pursuing business development deals is encouraging.
The company’s Specialty Care segment is on a strong footing, particularly with regular label expansion of Dupixent. Dupixent is now annualizing at around €2 billion in sales after just around two years in the market and could prove to be key long-term driver. The performance of the Vaccines and Consumer Healthcare franchises also improved of late.
Sanofi’s R&D pipeline is strong and has delivered important results with several positive data read-outs and the achievement of regulatory milestones this year. However, headwinds include weak performance of the Diabetes unit, generic competition for many drugs and slower-than-expected uptake of core products like Praluent.
(You can read the full research report on Sanofi here >>>)
Other noteworthy reports we are featuring today include Pioneer Natural Resources and Aqua America.
5 Stocks Set to Double
Each was hand-picked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2020. Each comes from a different sector and has unique qualities and catalysts that could fuel exceptional growth.
Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.
Today, See These 5 Potential Home Runs >>
Zacks Investment Research
800-767-3771 ext. 9339
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.